(PharmaNewsWire.Com, August 10, 2017 ) Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, Chronic obstructive pulmonary disease, chronic and acute bronchitis, Emphysema and cystic fibrosis. Some of the major drugs in the market include Advair /Seretide, Avastin, Singulair, montelukast, prednisone, and azithromycin.
The global respiratory diseases drugs market was estimated to be around $51 billion as of 2016. The respiratory diseases drugs market market made up around 5% of the overall pharmaceuticals market in 2016. The respiratory diseases drugs market was the eleventh market in the global pharmaceutical market in 2016.
Collaborations Top competitors in the respiratory diseases drugs market are strategically partnering and collaborating with other companies to broaden their product portfolio is a major trend in this market. For instance, in March 2017, AstraZeneca announced collaboration with Circassia Pharmaceuticals plc, (a UK based respiratory biopharmaceutical company) for the development and commercialisation of Tudorza and Duaklir in the US. Tudorza and Duaklir are used in the treatment of chronic obstructive pulmonary disease (COPD).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
